MRI-based Signatures for Survival Prediction in Cervical Cancer With Radiotherapy

NCT06197126 · tracked via the Priya Life Science China tracker

Sponsor

Fujian Cancer Hospital

Phase

Observational

Started

2024-01-01

Last updated

2024-01-09

Condition(s) studied

Cervical CancerRadiotherapyPrognostic ModelMRI

Investigational drug(s) / intervention(s)

Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .

Treatment mainly composed of external pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT) .: The chemotherapy regimens included cisplatin (40 mg/m2) or nedaplatin (80 mg/m2) monotherapy or combined with paclitaxel (135 mg/m2) every three weeks during radiotherapy.

Study summary

This study aims to validate the value of tumor involvement features based on MRI in cervical cancer, facilitate the development of a more appropriate model for risk stratification, and help patients with varying risk profiles make appropriate decisions in treatment selection and follow-up plans.

Eligibility

Sex

FEMALE

Min age

20 Years

Max age

85 Years

Healthy volunteers

Inclusion Criteria: * (1) pathologically confirmed CC, (2) initially treated in our center Exclusion Criteria: * (1) lack of pre-treatment MRI, (2) prior anti-tumor treatment, (3) pelvic surgery history, (4) incomplete therapy, (5) loss of follow-up

Primary outcome measure(s)

overall survival — 1-36 months
the interval from diagnostic day to death or the last follow-up

Trial sites (1)

Facility	City	Region	Status
Fujian Cancer Hospital	Fuzhou	Fujian

More Fujian Cancer Hospital trials in China

Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer Recruiting

A Study of Sintilimab Combined With Chemotherapy for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma Recruiting

Dalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line Treatment Recruiting

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI Starting soon

Neoadjuvant Iparomlimab and Tuvonralimab Plus Chemotherapy-eclipse for Locally Advanced Cervical Cancer (NICE-CC) Recruiting

Other trials for the same condition

Myeloprotection With Trilaciclib in Pan-cancer Population Starting soon

Induction Chemotherapy Plus Cadonilimab for Locally Advanced Cervical Cancer Active, not recruiting

En Bloc Resection Versus Separation Surgery Combined With Radiotherapy for the Treatment of Spinal Oligometastatic Tumor. Recruiting

BAT1308 Combined with Platinum-Based Chemotherapy± Bevacizumab for PDL1-Positive (CPS ≥1) Cervical Cancer Recruiting

Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06197126 on ClinicalTrials.gov ↗ ← All trials in China